CRISPR Piotroski F Score

CRSP
 Stock
  

USD 77.46  1.41  1.79%   

This module uses fundamental data of CRISPR Therapeutics to approximate its Piotroski F score. CRISPR Therapeutics F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of CRISPR Therapeutics AG. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about CRISPR Therapeutics financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Continue to CRISPR Therapeutics Altman Z Score, CRISPR Therapeutics Correlation, CRISPR Therapeutics Valuation, as well as analyze CRISPR Therapeutics Alpha and Beta and CRISPR Therapeutics Hype Analysis.
  
As of 11th of August 2022, Total Debt is likely to grow to about 242.8 M. Also, Debt Current is likely to grow to about 12.6 M. CRISPR Therapeutics Enterprise Value over EBIT is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Enterprise Value over EBIT of 13.00. As of 11th of August 2022, Enterprise Value over EBITDA is likely to grow to 13.50, while Current Ratio is likely to drop 19.30.
At this time, it appears that CRISPR Therapeutics' Piotroski F Score is Healthy. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
6.0
Piotroski F Score - Healthy
1
Current Return On AssetsPositiveFocus
2
Change in Return on AssetsIncreasedFocus
3
Cash Flow Return on AssetsPositiveFocus
4
Current Quality of Earnings (accrual)ImprovingFocus
5
Asset Turnover GrowthIncreaseFocus
6
Current Ratio ChangeDecreaseFocus
7
Long Term Debt Over Assets ChangeHigher LeverageFocus
8
Change In Outstending SharesDecreaseFocus
9
Change in Gross MarginNo ChangeFocus

CRISPR Therapeutics Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to CRISPR Therapeutics is to make sure CRISPR is not a subject of accounting manipulations and runs a healthy internal audit department. So, if CRISPR Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if CRISPR Therapeutics' financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares62.1 M75.9 M
Significantly Down
Increasing
Slightly volatile
Weighted Average Shares Diluted64.9 M80.4 M
Significantly Down
Increasing
Slightly volatile
Net Cash Flow from Operations581.5 M539 M
Significantly Up
Increasing
Slightly volatile
Total AssetsB2.8 B
Significantly Up
Increasing
Slightly volatile
Total Liabilities380.2 M352.4 M
Significantly Up
Increasing
Slightly volatile
Current Assets2.6 B2.4 B
Significantly Up
Increasing
Slightly volatile
Current Liabilities129.3 M119.9 M
Significantly Up
Increasing
Slightly volatile
Total Debt242.8 M225 M
Significantly Up
Increasing
Slightly volatile
Return on Average Assets0.160.145
Significantly Up
Increasing
Slightly volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile
Asset Turnover0.380.351
Significantly Up
Increasing
Slightly volatile

CRISPR Therapeutics F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between CRISPR Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards CRISPR Therapeutics in a much-optimized way.

About CRISPR Therapeutics Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Book Value per Share

34.09

CRISPR Therapeutics Book Value per Share is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Book Value per Share of 31.59

CRISPR Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of CRISPR Therapeutics from analyzing CRISPR Therapeutics' financial statements. These drivers represent accounts that assess CRISPR Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of CRISPR Therapeutics' important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Average Assets295.25 M433.88 M694.87 M1.34 B2.61 B2.81 B
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(63.58 M)(160.91 M)72.03 M(338.87 M)397.48 M428.86 M
Earnings Before Interest Taxes and Depreciation Amortization USD(63.58 M)(160.91 M)72.03 M(338.87 M)397.48 M428.86 M
Earnings before Tax(66.61 M)(164.43 M)67.31 M(348.06 M)379.53 M409.49 M
Average Equity194.94 M341.25 M569.7 M1.2 B2.33 B2.51 B
Enterprise Value706.46 M992.24 M2.77 B9.81 B4.98 B4.53 B
Free Cash Flow(77.91 M)(99.01 M)49.99 M(256.72 M)457.27 M493.37 M
Invested Capital13.58 M1.17 M113.14 M609.49 M1.92 B2.07 B
Invested Capital Average13.29 M5.81 M74.92 M295.1 M1.48 B1.6 B
Market Capitalization963.13 M1.48 B3.36 B10.82 B5.8 B5.29 B
Tangible Asset Value271 M488.73 M1.07 B1.83 B2.75 B2.97 B
Working Capital233.87 M438.65 M930.44 M1.62 B2.3 B2.48 B

About CRISPR Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze CRISPR Therapeutics AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CRISPR Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CRISPR Therapeutics AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 platform. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. CRISPR Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 473 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in CRISPR Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Price Ceiling Movement Now

   

Price Ceiling Movement

Calculate and plot Price Ceiling Movement for different equity instruments
All  Next Launch Module

Pair Trading with CRISPR Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CRISPR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with CRISPR Therapeutics

0.84ALTAltimmune Earnings Call  TodayPairCorr

Moving against CRISPR Therapeutics

0.85AGRXAgile Therapeutics Earnings Call  TodayPairCorr
0.78ABCAmerisourcebergen Corp Fiscal Year End 3rd of November 2022 PairCorr
0.71ACBAurora Cannabis Fiscal Year End 26th of September 2022 PairCorr
0.65NTNXNutanix Fiscal Year End 7th of September 2022 PairCorr
The ability to find closely correlated positions to CRISPR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CRISPR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CRISPR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CRISPR Therapeutics AG to buy it.
The correlation of CRISPR Therapeutics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CRISPR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CRISPR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CRISPR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to CRISPR Therapeutics Altman Z Score, CRISPR Therapeutics Correlation, CRISPR Therapeutics Valuation, as well as analyze CRISPR Therapeutics Alpha and Beta and CRISPR Therapeutics Hype Analysis. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
6.2 B
Quarterly Revenue Growth YOY
-1.0
Return On Assets
-0.15
Return On Equity
-0.27
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.